Sanofi closed 2025 with total sales of 43.626 billion euros, an increase of 9.9 percent.[2] In the fourth quarter, sales reached 11.3 billion euros, with growth of 13.3 percent, supported by new drugs and Dupixent.[1][2] The profit per share in this period was 1.53 euros.[1][2] The board of directors proposes a dividend of 4.12 euros per share, an increase of 5.1 percent.[2] The company announced a buyback of its own shares worth up to 1 billion euros in 2026.[2][4] For 2026, he expects high single-digit sales growth and faster earnings per share growth compared to sales.[2][3] CEO Paul Hudson said growth was sustained by new drugs and Dupixent, which hit a new quarterly high.[2]